<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836810</url>
  </required_header>
  <id_info>
    <org_study_id>ME/2008/3031</org_study_id>
    <nct_id>NCT00836810</nct_id>
  </id_info>
  <brief_title>Timed Release Tablet Prednisone in Polymyalgia Rheumatica</brief_title>
  <official_title>Circadian Variation in Cytokines and the Effect of Timed Release Tablet Prednisone in Polymyalgia Rheumatica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Bristol NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polymyalgia Rheumatica (PMR) is a disease that usually affects older people. Patients
      complain of stiffness and pain around the shoulders and hips. The stiffness is more severe in
      the morning.

      Research in Rheumatoid Arthritis (RA), which is also much worse in the mornings, has shown
      that IL−6 (a chemical messenger) peaks in the morning with very low levels in the evening.
      This may explain why stiffness is most severe in the morning. The investigators have recently
      shown that timed release tablet (TRT) prednisone reduced morning IL−6 levels close to normal
      in RA patients.

      In PMR, IL−6 levels are high. Given that both RA and PMR have the same variation of symptoms
      (worse in the morning); it's likely that PMR patients have the same variation in IL−6 levels.
      In a pilot study of 4 patients conducted within our department, IL−6 levels did, indeed, show
      a pattern similar to that found in RA patients, but the number of patients is small and the
      results need to be confirmed.

      PMR is treated with moderate doses of glucocorticoid for about 2 years. While generally
      abolishing symptoms, these doses are very likely to cause adverse effects such as high blood
      pressure, weight gain and diabetes. These side effects are much less frequent when lower
      doses are used but these are not sufficient to control PMR using traditional dosing regimes.

      Therefore, the investigators wish to investigate whether TRT prednisone in PMR will reduce
      IL−6 and morning symptoms similar to those in RA. The investigators think that it will do so,
      and will achieve symptomatic relief at a lower dose. If this is the case, then treating
      patients with lower doses may mean reduced risk of glucocorticoid induced side effects in the
      future.

      Patients will be recruited through the outpatient clinics at the University Hospitals
      Bristol, NHS Foundation Trust, Rheumatology Centre. Each patient will give fully informed
      consent after being given details of the study and a patient information sheet. The research
      doctor will take the consent 2−5 days after this information has been provided and with the
      presence of a witness. The study will consist of the collection and analysis of sequential
      blood samples over a 24 hour period on 2 occasions 2 weeks apart, taking TRT prednisone 7 mg
      / standard release prednisolone 7 mg for the intervening period. The investigators will aim
      to recruit 12 patients in each arm. A single blood sample will be taken when the patient
      comes for a routine review 2 weeks later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The volunteers will stay overnight in the Rheumatology Centre; 24-hour Research Facility on
      two occasions (Night A and Night B) 12-16 days apart. This slight flexibility will allow some
      leeway in arranging residency nights. In general the investigators will aim for 14 days.
      After Night A, each volunteer will be randomized (in pre-prepared sealed envelopes) to take
      one tablet morning or evening. Half the patients will take active standard release
      prednisolone in the morning. The other half will receive active TRT Prednisone 7mg to be
      taken each evening at 22:00 until the day after Night B. All study medication will then be
      discontinued and standard therapy (prednisolone 15mg each morning) commenced. Patients will
      be reviewed after 2 weeks to ensure expected clinical response and to measure IL-6 and other
      cytokines in the blood sample that is also needed to check the acute phase response.

      On Night A and Night B, volunteers will attend the Rheumatology Centre at 15:00.

      First, standard assessment tools will be used by the research doctor to assess the state of
      the patient's condition.

      These assessments will be:

        -  Morning stiffness (minutes)

        -  Pain (visual analogue scale)

        -  Patient's opinion of condition

        -  Clinician's opinion of condition

        -  Health Assessment Questionnaire

        -  BRAF-MDQ fatigue scale and the Hospital Anxiety and Depression Scale.

      An intravenous (IV) cannula will be inserted into the elbow area. At least one hour after the
      IV cannula is placed, but usually at 16:30, a blood sample (2ml) will be taken through the IV
      cannula and the cannula flushed. At 22:30 the main lights will be switched off and the
      volunteer encouraged to sleep. In total, 20 samples will be taken from the cannula over 24
      hours.

      The investigators will calculate mean and standard deviation (or non-parametric analysis if
      the data are not normally distributed) for blood cytokines for each time point. These mean
      and standard deviations will be compared for pre- and post-TRT prednisone samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Serum IL-6 Concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>Pre-treatment (Night A) peak minus post-treatment (Night B) peak. Peaks defined as the highest value for each patient from measures at 0, 1.5, 3, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5, 12.5, 13.5, 14.5, 15.5, 17, 19, 20.5, 22, and 24 hours after 16.30 on day before treatment (Night A) and last day of treatment (Night B) and the peak identified for each one.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Area Under the Curve (AUC) of Plasma IL-6</measure>
    <time_frame>24 hour measurements 2 weeks apart</time_frame>
    <description>Pre-treatment (Night A) AUC minus post-treatment (Night B) AUC. AUC calculated from measures at 0, 1.5, 3, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5, 12.5, 13.5, 14.5, 15.5, 17, 19, 20.5, 22, and 24 hours after 16.30 on day before treatment (Night A) and last day of treatment (Night B).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Morning Stiffness</measure>
    <time_frame>2 weeks</time_frame>
    <description>How long was your morning stiffness today? Pre-treatment (Night A) value minus post-treatment (Night B) value divided by pre-treatment value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (Severity)</measure>
    <time_frame>24 hour period after 2 weeks of treatment</time_frame>
    <description>100mm visual analogue scale. Question: How much pain have you had in the last 24 hours? Anchors: No pain; Severe pain. Min score 0, Max score 100. Higher value is worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Opinion of Condition</measure>
    <time_frame>Current value at baseline and after 2 weeks treatment</time_frame>
    <description>100mm visual analogue scale. Question: Considering all the ways your pain and/or stiffness affect(s) you, please mark on the line how well you are doing. Anchors: Very well; Very badly. Min 0 Max 100 (poor outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Opinion of Disease Activity.</measure>
    <time_frame>Current at baseline and after 2 weeks treatment</time_frame>
    <description>100mm visual analogue scale. Question: Clinician's opinion of disease activity. Anchors: None; Severe Min 0 Max 100 (worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Polymyalgia Rheumatica</condition>
  <arm_group>
    <arm_group_label>Timed Release Tablet Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timed Release Tablet Prednisone</intervention_name>
    <description>Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
    <arm_group_label>Timed Release Tablet Prednisone</arm_group_label>
    <other_name>Lodotra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
    <arm_group_label>Standard Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PMR by standard criteria. The Bird criteria will be used. 3 or more
             features are required to make the diagnosis.

               -  Bilateral shoulder pain/stiffness

               -  Duration of symptoms &lt;2/52

               -  Initial ESR &gt;40 mm/h

               -  Stiffness &gt;1 h

               -  Age &gt;65 years

               -  Depression and/or weight loss

               -  Bilateral upper arm tenderness

          -  Are over 50 but less than 85 years old.

          -  No or stable NSAID or analgesic therapy for at least 7 days.

          -  Currently active disease defined by a CRP at least 10mg/L, ESR at least 29mm in one
             hour or PV &gt;1.72

        Exclusion Criteria:

          -  Currently on oral glucocorticoid treatment or taken within 2 months

          -  Parenteral glucocorticoid treatment with the last 2 months

          -  Pregnancy and lactation

          -  Inflammatory diseases such as inflammatory bowel disease, colitis, asthma

          -  Co-existent giant cell arteritis

          -  Other auto-immune diseases

          -  Cancer

          -  Infections, treatment with antibiotics within the past 6 weeks

          -  Significant renal disease (creatinine &gt;150 μmol/L)

          -  Significant hepatic impairment

          -  Participation in a clinical trial within the past 30 days

          -  Working shift employee

          -  Jet lag
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Kirwan, MBBS,MD,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Bristol NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>February 1, 2017</results_first_submitted>
  <results_first_submitted_qc>July 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2018</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circadian variations of cytokines in PMR</keyword>
  <keyword>effect of TRT Prednisone in cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of 35 sequential eligible patients invited to participate 12 agreed to do so.</recruitment_details>
      <pre_assignment_details>One patient was a technical failure (unable to take 24 hour blood samples) before the treatment randomisation step, leaving 11 patients included.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Timed Release Tablet Prednisone</title>
          <description>11 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
        </group>
        <group group_id="P2">
          <title>Standard Prednisolone</title>
          <description>11 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">1 patient was subsequently diagnosed with SLE and, per protocol, was not included.</participants>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>New diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fewer participants were recruited than anticipateed within the time frame of the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Timed Release Tablet Prednisone</title>
          <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
        </group>
        <group group_id="B2">
          <title>Standard Prednisolone</title>
          <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.5" lower_limit="67" upper_limit="79"/>
                    <measurement group_id="B2" value="72.5" lower_limit="67" upper_limit="79"/>
                    <measurement group_id="B3" value="76" lower_limit="67" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>plasma IL-6 peak values (pg/ml)</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="46.7"/>
                    <measurement group_id="B2" value="40.1" spread="22.3"/>
                    <measurement group_id="B3" value="45.5" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>plasma IL-6 AUC</title>
          <units>pg*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191" spread="232"/>
                    <measurement group_id="B2" value="236" spread="246"/>
                    <measurement group_id="B3" value="218" spread="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>plasma viscosity (mPa.s)</title>
          <units>mPa.s</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.77" lower_limit="1.73" upper_limit="1.9"/>
                    <measurement group_id="B2" value="1.875" lower_limit="1.75" upper_limit="2.13"/>
                    <measurement group_id="B3" value="1.8" lower_limit="1.73" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Morning stiffness</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="38.7"/>
                    <measurement group_id="B2" value="115" spread="55"/>
                    <measurement group_id="B3" value="96.7" spread="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain</title>
          <description>VAS 0mm (better) -100mm (worse)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="23.6"/>
                    <measurement group_id="B2" value="62.2" spread="15.0"/>
                    <measurement group_id="B3" value="59.2" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's opinion of condition</title>
          <units>VAS 0mm (better) - 100mm (worse)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="29.3"/>
                    <measurement group_id="B2" value="64.2" spread="16.3"/>
                    <measurement group_id="B3" value="60.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinician's opinion of disease activity</title>
          <units>VAS 0mm (better) - 100mm (worse)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="23.6"/>
                    <measurement group_id="B2" value="62.0" spread="15.0"/>
                    <measurement group_id="B3" value="59.1" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Polymyalgia Rheumatica Disease Activity Score</title>
          <description>PMR Disease Activity Score (PMR-AS). Formula:
PMR-AS = C-reactive protein (mg/L) + visual analogue scale, patient (0[better]-10[worse] cm) + visual analogue scale, physician (0[better]-10[worse] cm) + morning stiffness (min) x 0.1 + elevation of the upper limbs (3 = none; 2 = below shoulder girdle; 1 = up to shoulder girdle; 0 = above shoulder girdle)
A score below 7 implies low disease activity, a score range of 7 – 17 reflects medium activity and a score of more than 17 indicates an active disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="8.7"/>
                    <measurement group_id="B2" value="47.1" spread="22.2"/>
                    <measurement group_id="B3" value="39.9" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Peak Serum IL-6 Concentration</title>
        <description>Pre-treatment (Night A) peak minus post-treatment (Night B) peak. Peaks defined as the highest value for each patient from measures at 0, 1.5, 3, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5, 12.5, 13.5, 14.5, 15.5, 17, 19, 20.5, 22, and 24 hours after 16.30 on day before treatment (Night A) and last day of treatment (Night B) and the peak identified for each one.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timed Release Tablet Prednisone</title>
            <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
          </group>
          <group group_id="O2">
            <title>Standard Prednisolone</title>
            <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Serum IL-6 Concentration</title>
          <description>Pre-treatment (Night A) peak minus post-treatment (Night B) peak. Peaks defined as the highest value for each patient from measures at 0, 1.5, 3, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5, 12.5, 13.5, 14.5, 15.5, 17, 19, 20.5, 22, and 24 hours after 16.30 on day before treatment (Night A) and last day of treatment (Night B) and the peak identified for each one.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="8.3"/>
                    <measurement group_id="O2" value="29.3" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A priory test for statistical significance was P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>A priori statistical significance set as P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Area Under the Curve (AUC) of Plasma IL-6</title>
        <description>Pre-treatment (Night A) AUC minus post-treatment (Night B) AUC. AUC calculated from measures at 0, 1.5, 3, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5, 12.5, 13.5, 14.5, 15.5, 17, 19, 20.5, 22, and 24 hours after 16.30 on day before treatment (Night A) and last day of treatment (Night B).</description>
        <time_frame>24 hour measurements 2 weeks apart</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timed Release Tablet Prednisone</title>
            <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
          </group>
          <group group_id="O2">
            <title>Standard Prednisolone</title>
            <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Area Under the Curve (AUC) of Plasma IL-6</title>
          <description>Pre-treatment (Night A) AUC minus post-treatment (Night B) AUC. AUC calculated from measures at 0, 1.5, 3, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5, 12.5, 13.5, 14.5, 15.5, 17, 19, 20.5, 22, and 24 hours after 16.30 on day before treatment (Night A) and last day of treatment (Night B).</description>
          <units>pg*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.5" spread="77.7"/>
                    <measurement group_id="O2" value="97.9" spread="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>A priori statistical significance set at P&lt;0.05</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Morning Stiffness</title>
        <description>How long was your morning stiffness today? Pre-treatment (Night A) value minus post-treatment (Night B) value divided by pre-treatment value.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timed Release Tablet Prednisone</title>
            <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
          </group>
          <group group_id="O2">
            <title>Standard Prednisolone</title>
            <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Morning Stiffness</title>
          <description>How long was your morning stiffness today? Pre-treatment (Night A) value minus post-treatment (Night B) value divided by pre-treatment value.</description>
          <units>percentage of baseline morning stiffness</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="38.7"/>
                    <measurement group_id="O2" value="115.0" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0906</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain (Severity)</title>
        <description>100mm visual analogue scale. Question: How much pain have you had in the last 24 hours? Anchors: No pain; Severe pain. Min score 0, Max score 100. Higher value is worse outcome.</description>
        <time_frame>24 hour period after 2 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timed Release Tablet Prednisone</title>
            <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
          </group>
          <group group_id="O2">
            <title>Standard Prednisolone</title>
            <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain (Severity)</title>
          <description>100mm visual analogue scale. Question: How much pain have you had in the last 24 hours? Anchors: No pain; Severe pain. Min score 0, Max score 100. Higher value is worse outcome.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="25.3"/>
                    <measurement group_id="O2" value="19.5" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Opinion of Condition</title>
        <description>100mm visual analogue scale. Question: Considering all the ways your pain and/or stiffness affect(s) you, please mark on the line how well you are doing. Anchors: Very well; Very badly. Min 0 Max 100 (poor outcome).</description>
        <time_frame>Current value at baseline and after 2 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timed Release Tablet Prednisone</title>
            <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
          </group>
          <group group_id="O2">
            <title>Standard Prednisolone</title>
            <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Opinion of Condition</title>
          <description>100mm visual analogue scale. Question: Considering all the ways your pain and/or stiffness affect(s) you, please mark on the line how well you are doing. Anchors: Very well; Very badly. Min 0 Max 100 (poor outcome).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="20.6"/>
                    <measurement group_id="O2" value="26.0" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician's Opinion of Disease Activity.</title>
        <description>100mm visual analogue scale. Question: Clinician's opinion of disease activity. Anchors: None; Severe Min 0 Max 100 (worse)</description>
        <time_frame>Current at baseline and after 2 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timed Release Tablet Prednisone</title>
            <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
          </group>
          <group group_id="O2">
            <title>Standard Prednisolone</title>
            <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician's Opinion of Disease Activity.</title>
          <description>100mm visual analogue scale. Question: Clinician's opinion of disease activity. Anchors: None; Severe Min 0 Max 100 (worse)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="18.1"/>
                    <measurement group_id="O2" value="20.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.003</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.001</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>A priori statistical significance set at P&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 week duration of treatment and 2 weeks of standard treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Timed Release Tablet Prednisone</title>
          <description>Patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
Timed Release Tablet Prednisone: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.</description>
        </group>
        <group group_id="E2">
          <title>Standard Prednisolone</title>
          <description>Patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
Prednisolone: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of patients not blind to study treatment which may have influenced reports of morning stiffness.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor John Kirwan</name_or_title>
      <organization>University of Bristol</organization>
      <phone>+44 117 342 2904</phone>
      <email>John.Kirwan@Bristol.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

